Login / Signup

Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.

Sehhoon ParkDongryul OhYoon-La ChoiSang Ah ChiKyunga KimMyung-Ju AhnJong-Mu Sun
Published in: Cancer (2022)
Durvalumab and tremelimumab with definitive CCRT had promising efficacy in patients with locally advanced ESCC. In addition, PD-L1 expression had strong predictive value in the study population.
Keyphrases
  • locally advanced
  • rectal cancer
  • neoadjuvant chemotherapy
  • squamous cell carcinoma
  • radiation therapy
  • phase ii study
  • clinical trial
  • lymph node
  • double blind